<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933435</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00089525_1</org_study_id>
    <nct_id>NCT04933435</nct_id>
  </id_info>
  <brief_title>Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients</brief_title>
  <official_title>Phase II Non-Randomized Trial of Interventional Radiology Liver Directed Therapies and Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study to evaluate change in Quality of Life, as defined by the European&#xD;
      Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30&#xD;
      (EORTC C-30), from baseline to 1 month post treatment in two patient cohorts receiving&#xD;
      Interventional Radiology Liver Directed Therapies or Hypofractionated Image-Guided Radiation&#xD;
      Therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">November 2025</completion_date>
  <primary_completion_date type="Anticipated">November 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in quality of life in patient cohorts receiving either Interventional Radiology Liver Directed Therapies or Hypofractionated Image-Guided Radiation Therapy</measure>
    <time_frame>baseline, 1 month, 3 months, 6 months</time_frame>
    <description>as defined by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC C-30) measured from not at all (better) to very much (worse)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in quality of life in patients receiving Interventional Radiology Liver Directed Therapies or HIGRT</measure>
    <time_frame>baseline, 1 month, 3 months, 6 months</time_frame>
    <description>as measured by the FACT-Hep survey questionnaire from not at all (better) to very much (worse)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with grade ≥2 acute toxicity that received Interventional Liver Directed Therapy</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with grade ≥2 acute toxicity that received Hypofractionated Image Guided Radiation Therapy</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total healthcare system cost associated with Interventional Radiology Liver Directed Therapies</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total healthcare system cost associated with Hypofractionated Liver Directed Therapy</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Interventional Radiology Liver Directed Therapies (ILDT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ILDT includes ablations such as microwave ablation and percutaneous local ablation and embolotherapies including bland embolization, chemoembolization and radioembolization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypofractionated Image-Guided Radiation Therapy (HIGRT)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HIGRT is a non-invasive, outpatient procedure typically delivered in 3-10 fractions of radiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of life questionnaires</intervention_name>
    <description>European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep)</description>
    <arm_group_label>Hypofractionated Image-Guided Radiation Therapy (HIGRT)</arm_group_label>
    <arm_group_label>Interventional Radiology Liver Directed Therapies (ILDT)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HCC diagnosed either by histology/pathology or Liver Imaging Reporting and Data System&#xD;
             (LIRADs 5 per the ACR's LIRADs criteria 10) by CT or MRI&#xD;
&#xD;
          -  Patient is 18 years or older&#xD;
&#xD;
          -  ECOG Performance status of 0-2&#xD;
&#xD;
          -  Child Pugh score A5, A6, B7 or B8 (see Appendix)&#xD;
&#xD;
          -  Lesion ≤ 5cm in size&#xD;
&#xD;
          -  ≤ 3 lesions in the liver to be treated on protocol&#xD;
&#xD;
          -  Lesion amenable to treatment with both Interventional Radiology Liver Directed&#xD;
             Therapies and HIGRT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Child Pugh score B9 or Class C&#xD;
&#xD;
          -  Fluctuating ascites&#xD;
&#xD;
          -  Inability to complete baseline Quality of Life survey forms&#xD;
&#xD;
          -  Concurrent administration of systemic therapy for hepatocellular carcinoma&#xD;
&#xD;
          -  Prior liver radiation therapy is an exclusion unless subject participation is approved&#xD;
             by the PI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manisha Palta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Scott Andrews, RN BSN</last_name>
    <phone>(919) 668-3726</phone>
    <email>william.s.andrews@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linda Kaltenbach</last_name>
    <phone>(919) 681-6804</phone>
    <email>linda.kaltenbach@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Durham Veterans Administration Health Care System (DVAHCS)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Andrews, BSN RN</last_name>
      <email>William.Andrews1@va.gov</email>
    </contact>
    <investigator>
      <last_name>Manisha Palta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Andrews, RN BSN</last_name>
      <phone>919-668-3726</phone>
      <email>william.s.andrews@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Manisha Palta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

